AIM: To test the effect of atorvastatin (ATV) and ATV plus ω-3 FAEEs on VLDL-TG metabolism in obese, insulin resistant men. METHODS: We carried out a 6-week randomized, placebo-controlled study to examine the effect of ATV (40 mg/day) and ATV plus ω-3 FAEEs (4 g/day) on VLDL-TG metabolism in 36 insulin resistant obese men. VLDL-TG kinetics were determined using d5 -glycerol, gas chromatography-mass spectrometry and compartmental modelling. RESULTS: Compared with the placebo, ATV significantly decreased VLDL-TG concentration (-40%, p < 0.001) by increasing VLDL-TG fractional catabolic rate (FCR) (+47%, p < 0.01). ATV plus ω-3 FAEEs lowered VLDL-TG concentration to a greater degree compared with placebo (-46%, p < 0.001) or ATV monotherapy (-13%, p = 0.04). This was achieved by a reduction in VLDL-TG production rate (PR) compared with placebo (-32%, p = 0.008) or ATV (-20%, p = 0.03) as well as a reciprocal increase in VLDL-TG FCR (+42%, p < 0.05) compared with placebo. CONCLUSION: In insulin resistant, dyslipidaemic, obese men, ATV improves VLDL-TG metabolism by increasing VLDL-TG FCR. The addition of 4 g/day ω-3 FAEE to statin therapy provides further TG-lowering by lowering VLDL-TG PR.
RCT Entities:
AIM: To test the effect of atorvastatin (ATV) and ATV plus ω-3 FAEEs on VLDL-TG metabolism in obese, insulin resistant men. METHODS: We carried out a 6-week randomized, placebo-controlled study to examine the effect of ATV (40 mg/day) and ATV plus ω-3 FAEEs (4 g/day) on VLDL-TG metabolism in 36 insulin resistant obesemen. VLDL-TG kinetics were determined using d5 -glycerol, gas chromatography-mass spectrometry and compartmental modelling. RESULTS: Compared with the placebo, ATV significantly decreased VLDL-TG concentration (-40%, p < 0.001) by increasing VLDL-TG fractional catabolic rate (FCR) (+47%, p < 0.01). ATV plus ω-3 FAEEs lowered VLDL-TG concentration to a greater degree compared with placebo (-46%, p < 0.001) or ATV monotherapy (-13%, p = 0.04). This was achieved by a reduction in VLDL-TG production rate (PR) compared with placebo (-32%, p = 0.008) or ATV (-20%, p = 0.03) as well as a reciprocal increase in VLDL-TG FCR (+42%, p < 0.05) compared with placebo. CONCLUSION: In insulin resistant, dyslipidaemic, obesemen, ATV improves VLDL-TG metabolism by increasing VLDL-TG FCR. The addition of 4 g/day ω-3 FAEE to statin therapy provides further TG-lowering by lowering VLDL-TG PR.
Authors: Bianca Scolaro; Marina S Nogueira; Aline Paiva; Adriana Bertolami; Lucia P Barroso; Tomas Vaisar; Sean P Heffron; Edward A Fisher; Inar A Castro Journal: Mol Metab Date: 2018-02-20 Impact factor: 7.422
Authors: Ji Eun Jun; In Kyung Jeong; Jae Myung Yu; Sung Rae Kim; In Kye Lee; Kyung Ah Han; Sung Hee Choi; Soo Kyung Kim; Hyeong Kyu Park; Ji Oh Mok; Yong Ho Lee; Hyuk Sang Kwon; So Hun Kim; Ho Cheol Kang; Sang Ah Lee; Chang Beom Lee; Kyung Mook Choi; Sung Ho Her; Won Yong Shin; Mi Seung Shin; Hyo Suk Ahn; Seung Ho Kang; Jin Man Cho; Sang Ho Jo; Tae Joon Cha; Seok Yeon Kim; Kyung Heon Won; Dong Bin Kim; Jae Hyuk Lee; Moon Kyu Lee Journal: Diabetes Metab J Date: 2019-06-20 Impact factor: 5.376
Authors: E Theusch; K Kim; K Stevens; J D Smith; Y-D I Chen; J I Rotter; D A Nickerson; M W Medina Journal: Pharmacogenomics J Date: 2016-03-01 Impact factor: 3.245